Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449555 | 0.92 | ALDH1A1 (0.57) | ALDH1A1GAAKDM4ESIGMAR1MEN1 | |
| SCHEMBL2438027 | 0.86 | ALDH1A1 (0.61) | ALDH1A1GAAKDM4EMAPK1CNR2 | |
| SCHEMBL13932969 | 0.84 | ALDH1A1 (0.55) | ALDH1A1GAAKDM4EHTTPDCD1 | |
| SCHEMBL12891076 | 0.82 | ALDH1A1 (0.53) | ALDH1A1GAAKDM4EHTTXBP1 | |
| SCHEMBL12449569 | 0.82 | ALDH1A1 (0.53) | ALDH1A1GAAKDM4EHTTXBP1 | |
| SCHEMBL19710807 | 0.81 | BCHE (0.56) | ALDH1A1KDM4EHTTPDCD1CD274 | |
| SCHEMBL12449572 | 0.81 | ALDH1A1 (0.54) | ALDH1A1GAAKDM4ECNR2SIGMAR1 | |
| SCHEMBL8212538 | 0.81 | BCHE (0.56) | ALDH1A1KDM4EHTTPDCD1CD274 | |
| SCHEMBL12449589 | 0.81 | MCHR1 (0.46) | ALDH1A1GAAKDM4ESIGMAR1TEAD1 | |
| SCHEMBL22243517 | 0.80 | ALDH1A1 (0.53) | ALDH1A1GAAKDM4EHTTXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | ALDH1A1 4640/4885GAA 2157/4885KDM4E 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.